The global islet amyloid polypeptide market is anticipated to grow at a significant CAGR 2.4% during the forecast period (2022-2028). The islet amyloid polypeptide (or commonly known as amylin) is a type of hormone that plays a key role in glucose homeostasis though it aggregates to form islet amyloid in type-2 diabetes. Its formation contributes to ß-cell dysfunction and death due to the disease and to the failure of islet transplants. Clinical trials show a role for islet amyloid polypeptide aggregation in cardio related complications of type-2 diabetes and further highlights a possible role in type-1 diabetes. The major factor attributed to the market growth includes the growing prevalence of hormonal disorders, the increasing geriatric population base, coupled with advancements in polypeptides. The increasing prevalence of hormonal disorders such as diabetes mellitus led to an increased role of islet amyloid polypeptide to regulate these conditions. 

In 2018, about 30 million people in the US had diabetes, as per the IDF (International Diabetes Federation). Further, in 2019, the total adult population in the US with diabetes was 31 million while in Canada was 2.8 million. The US has the largest population of children and adolescents with type 1 diabetes (175,900). Moreover, there were around 189,000 mortalities due to diabetes in the US in 2019, which represents one of the highest numbers of mortalities around the globe. Adding to this, islet amyloid polypeptide also holds significant application in treating gastrointestinal disorder, metabolic disorders, musculoskeletal disorders, among various others.

Market Coverage

• The market number available for – 2021-2028

• Base year- 2021

• Forecast period- 2022-2028

• Segment Covered- 

o By Type

o By Application

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape:  Eli Lilly and Co., and AstraZeneca plc, among others. 

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How are players addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Islet Amyloid Polypeptide Market Report by Segment

By Type

• AC-253

• DACRA-042

• DACRA-089

• KBP-056

• KBP-058

• Others

By Application

• Metabolic Disorders

• Gastrointestinal

• Musculoskeletal Disorders

• Others

Global Islet Amyloid Polypeptide Market Report by Region

North America       

• US

• Canada

Europe

• Germany

• UK

• France

• Spain

• Italy

• Rest of Europe

Asia-Pacific    

• China

• Japan

• India

• Rest of Asia-Pacific

Rest of the World

• Latin America

• Middle East and Africa